aTyr Pharma Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. Details of the presentations appear below.

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune suppression, setting it apart from traditional treatments, with promising post-hoc results in higher doses. aTyr is well-funded with $81 million in cash, sufficient for upcoming trial readouts, and has seen significant stock performance and insider buying.

aTyr Pharma: The Bull Has Finally Come Out

San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.

aTyr Pharma to Present at the LD Micro Main Event XVII in October

Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025.

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Everett, MAFormat: 1x1 Investor Meetings Conference: H.C.

aTyr Pharma to Participate in September Investor Conferences

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments.

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Here is how Atyr Pharma (ATYR) and High Tide Inc. (HITI) have performed compared to their sector so far this year.

Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year?

aTyr Pharma

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

News for aTyr Pharma Inc Stock (ATYR)